Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Oncology

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(16)00150-9PMID 27108243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

  2015cited by this paper
• A 21-year-old patient with a HER2-positive colorectal cancer.

  2015cited by this paper
• Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer

  2015cited by this paper
• Metastatic colorectal cancer: current state and future directions.

  2015cited by this paper
• Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

  2015cited by this paper
• Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

  2015cited by this paper
• Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

  2015cited by this paper
• Abstract 659: Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas

  2015cited by this paper
• Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

  2014cited by this paper
• Biomarkers of drugs targeting HER‐family signalling in cancer

  2014cited by this paper
• Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

  2014cited by this paper
• Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

  2014cited by this paper
• High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

  2014cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

  2013cited by this paper
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Comprehensive molecular characterization of human colon and rectal cancer

  2012cited by this paper
• Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

  2011cited by this paper
• A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

  2011cited by this paper
• Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal Cancer

  2011cited by this paper
• OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

  2011cited by this paper
• Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

  2011cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cited by this paper
• An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests.

  2009cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial

  2004cited by this paper
• Sample size tables for exact single‐stage phase II designs

  2001cited by this paper
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper
• Evaluating the yield of medical tests.

  1982cited by this paper

• Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

  2026cites this paper
• HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study

  2026cites this paper
• Molecular Advances in Gastrointestinal Pathology.

  2026cites this paper
• Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

  2026cites this paper
• Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP).

  2026cites this paper
• Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.

  2026cites this paper
• Integrated Molecular Profiling of Colorectal Cancer by Tumor Location: Evidence from a Real-World Cohort with Primary and Metastatic Samples.

  2026cites this paper
• Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis

  2026cites this paper
• HER2 testing in multiple solid tumor types: concordance of immunohistochemistry scores between three HER2 scoring algorithms.

  2026cites this paper
• Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer

  2026cites this paper
• Association between oxaliplatin infusion timing and outcomes with first-line XELOX in colorectal cancer: a retrospective cohort study

  2026cites this paper
• Radiomics-based Machine Learning Approach to Predict Chemotherapy Responses in Colorectal Liver Metastases

  2025cites this paper
• Current and emerging concepts for systemic treatment of metastatic colorectal cancer

  2025cites this paper
• Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

  2025cites this paper
• Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study

  2025cites this paper
• Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer

  2025cites this paper
• Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial

  2025cites this paper
• Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis

  2025influential citation
• Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study

  2025cites this paper
• Case Report: T-Dxd plus bevacizumab in a patient with brain metastases from rectal cancer with HER2 amplification

  2025cites this paper
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer

  2025cites this paper
• Concurrent Biopsy During Liver-Directed Therapy: Considerations, Techniques, and Expanding Role in Clinical Practice

  2025cites this paper
• Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?

  2025cites this paper
• Characterization of the Tumor Immune Microenvironment in HER2-Positive Colorectal Cancer: Association With Prognostic and Therapeutic Implications.

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• A New Hope: Dual Human Epidermal Growth Factor Receptor 2 Blockade and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Amplified Colorectal Cancer – A Case Report and Literature Review

  2025influential citation
• Digestive cancers: mechanisms, therapeutics and management

  2025cites this paper
• A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database

  2025cites this paper
• Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report

  2025cites this paper
• Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions

  2025cites this paper
• Molecular Targets in Metastatic Colorectal Cancer: A Review

  2025cites this paper
• Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment

  2025cites this paper
• HER2-positive, RAS-mutant, MSS colorectal cancer: a rare subtype report and novel insights into immunotherapy and ADC combinations.

  2025cites this paper
• HER2, HER3 and mismatch repair protein expression in stage IV small bowel adenocarcinoma: results from a multicenter series.

  2025cites this paper
• Evaluation of HER2 expression in prostate cancer among Mexican patients.

  2025cites this paper
• Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study

  2025cites this paper
• Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization

  2025cites this paper
• Prognostic Factors in Colorectal Liver Metastases: An Exhaustive Review of the Literature and Future Prospectives

  2025cites this paper
• Kolon – Was gibt es Neues beim fortgeschrittenen kolorektalen Karzinom?

  2025cites this paper
• Immunotherapy for precision medicine in colorectal cancer

  2025cites this paper
• Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.

  2025cites this paper
• Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers

  2025cites this paper
• Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies

  2025influential citation
• Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board

  2025cites this paper
• Antibody treatments for digestive cancers: Past, present, and future.

  2025cites this paper
• Bias correction in treatment effect estimates following data-driven biomarker cutoff selection

  2025cites this paper
• Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.

  2025cites this paper
• Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

  2025cites this paper
• NSUN2 promotes colorectal cancer progression and increases lapatinib sensitivity by enhancing CUL4B/ErbB‐STAT3 signalling in a non‐m5C manner

  2025cites this paper
• Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects

  2025cites this paper
• Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries

  2025cites this paper
• State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives

  2025cites this paper
• HER2 testing: evolution and update for a companion diagnostic assay

  2025influential citation
• Zinc oxide nanoparticle conjugated with Lapatinib has apoptogenic effect on colon cancer cell line

  2025cites this paper
• Oncogenic mutations of clinical significance in colorectal cancer.

  2025cites this paper
• Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

  2025cites this paper
• Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial

  2025cites this paper
• Claudin 18.2 Expression in 1,404 Digestive Tract Adenocarcinomas including 1,175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes are Claudin 18.2 Positive.

  2025cites this paper
• Tendomodulin in pan-cancer analysis: exploring its impact on immune modulation and uncovering functional insights in colorectal cancer

  2025cites this paper
• Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches

  2025cites this paper
• Clinical Actionability of Genes in Gastrointestinal Tumors

  2025cites this paper
• Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics

  2025cites this paper
• NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

  2025cites this paper
• Assessment of HER2/Neu Expression in Colorectal Carcinomas and Its Correlation With Tumor Stage and Histopathology

  2025cites this paper
• A case report of HER2-positive descending colon cancer with peritoneal metastasis and literature review

  2025cites this paper
• Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer

  2025cites this paper
• European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’

  2025cites this paper
• Advancements and challenges in biomarker testing for tumors of the luminal gastrointestinal tract: current practice guidelines and emerging markers

  2025cites this paper
• Beneath the surface of Colorectal Cancer: unmasking the evolving nature of (Neo)RAS.

  2025cites this paper
• Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report

  2025cites this paper
• Research hotspots and emerging trends in targeted therapy for colorectal cancer: a bibliometric analysis (2000–2023)

  2025cites this paper
• Investigation of the cytotoxic effects and mechanisms of the SLC39A6-targeting ADC drug BRY812 in CRC

  2025cites this paper
• Navigating beyond the surface - prognostic significance of KRAS, NRAS, BRAF, PIK3CA, and TP53 mutations examined by exons

  2025cites this paper
• Metastatic hepatic carcinoma: Mechanisms, emerging therapeutics, and future perspectives

  2025cites this paper
• Radical treatment for metastasis of HER2-positive rectal adenocarcinoma to the liver: A case report and literature review

  2025cites this paper
• NRG/ErbB signaling: on the trail of a molecular fingerprint in mucinous carcinoma

  2025cites this paper
• Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.

  2025cites this paper
• An update on pharmacotherapies for colorectal cancer: 2023 and beyond

  2024cites this paper
• Clinical-Molecular Characteristics and Post-Translational Modifications of Colorectal Cancer in North China: Implications for Future Targeted Therapies.

  2024cites this paper
• Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers

  2024cites this paper
• Treatment options for HER2-expressing colorectal cancer: updates and recent approvals

  2024influential citation
• Thérapie ciblée en cancérologie digestive

  2024cites this paper
• Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer

  2024cites this paper
• Assessment and treatment considerations for patients with colorectal liver metastases: AHPBA consensus guideline and update for surgeons.

  2024cites this paper
• Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations

  2024cites this paper
• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

  2024influential citation
• ERBB2 comprehensive profiling and prognostication in Stage III Colon Cancer: Findings from PETACC8 and IDEA-France cohorts.

  2024cites this paper
• Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review

  2024cites this paper
• Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study

  2024cites this paper
• Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

  2024cites this paper
• Evidence for Unified Assessment Criteria of HER2 IHC in Colorectal Carcinoma.

  2024cites this paper
• Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?

  2024cites this paper
• Predictive biomarkers in colorectal adenocarcinoma – a Brazilian perspective on current and future practices

  2024cites this paper
• Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions.

  2024cites this paper
• The emerging HER2 landscape in Colorectal Cancer: the key to unveil the future treatment algorithm?

  2024cites this paper
• Deciphering the functional landscape and therapeutic implications of noncoding RNAs in the TGF-β signaling pathway in colorectal cancer: A comprehensive review.

  2024cites this paper
• Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis.

  2024cites this paper
• First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?

  2024cites this paper
• Injectable nanocomposite hydrogel with cascade drug release for treatment of uveal melanoma.

  2024cites this paper
• Engineering and targeting potential of CAR NK cells in colorectal cancer

  2024cites this paper